Arbutus Announces Corporate Update and First Quarter 2018 Financial Results
May 03, 2018 16:00 ET
|
Arbutus Biopharma Corporation
Two Novel HBV Candidates Planned to Enter Clinical Development in 2018GalNAc Conjugated RNAi Agent Nominated to Enter IND-Enabling Studies Strategic Partnership with Roivant to Launch Genevant, an RNA...
Apricus Biosciences Announces Outcome of Vitaros™ End-of-Review Meeting with FDA
April 16, 2018 07:00 ET
|
Apricus Biosciences, Inc.
FDA Confirms Vitaros Regulatory Pathway Company Seeking Partner to Develop Vitaros in U.S. Company Evaluating Strategic Alternatives SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus...
Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases
April 11, 2018 17:24 ET
|
Arbutus Biopharma Corporation
Genevant aims to advance 5-10 product candidates into the clinic by 2020 across RNAi, mRNA, and gene editing modalities using Arbutus’ LNP and ligand conjugate platformsGenevant will be led by...
Vera Bradley Announces New Licensing Agreement for Sleepwear/Loungewear
March 14, 2018 09:00 ET
|
Vera Bradley, Inc.
FORT WAYNE, Ind., March 14, 2018 (GLOBE NEWSWIRE) -- Vera Bradley, Inc. (Nasdaq:VRA) (“Vera Bradley” or the “Company”), the iconic accessories and lifestyle brand, today announced it has entered...
Arbutus Settles Litigation, Terminating Acuitas’ Rights to LNP Technology
February 22, 2018 16:35 ET
|
Arbutus Biopharma Corporation
Acuitas has No Further Rights to Use or Sublicense Arbutus LNP TechnologyArbutus Consolidates LNP Patent Estate Enabling RNAi, mRNA, and Gene-editing Therapeutics VANCOUVER, B.C. and WARMINSTER, Pa.,...
Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™
February 16, 2018 07:00 ET
|
Apricus Biosciences, Inc.
SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the...
Arbutus Enters Exclusivity Agreement with Roivant Sciences
February 14, 2018 20:50 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran
November 16, 2017 13:40 ET
|
Arbutus Biopharma Corporation
VANCOUVER, B.C. and WARMINSTER, Pa., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company,...
Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)
November 13, 2017 17:22 ET
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus Announces Corporate Update and Third Quarter 2017 Financial Results
November 02, 2017 16:00 ET
|
Arbutus Biopharma Corporation
Strategic Investment from Roivant Extends Cash RunwayCombination Study for ARB-1467 Starting in 4Q17Company to Host a Corporate Update Conference Call Today at 4:15 PM ET VANCOUVER, British Columbia...